After adjusting for baseline characteristics, IGFBP-1 plasma concentration remained independently associated with 2-year MACE in patients with PAD (adjusted HR 1.57; 95% CI 1.21–1.97; p = 0.012). This evidence concerns the gene IGFBP1 and peripheral arterial disease.